EASL

Arrowhead Pharmaceuticals to Participate in Upcoming June 2023 Conferences

Retrieved on: 
Tuesday, June 6, 2023
Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Genetics, Clinical Trials, Arrowhead, EASL, Goldman, Liver disease, Goldman Sachs, Congress, European Association for the Study of the Liver, Conference, Pharmaceutical industry, Dietary supplement, Liver

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events:

Key Points: 
  • Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events:
    Jefferies Global Healthcare Conference – June 8, 2023
    Goldman Sachs 44th Annual Global Healthcare Conference – June 12, 2023
    European Association for the Study of the Liver (EASL) Congress 2023 – June 24, 2023
    Title: Fazirsiran reduces liver Z-alpha-1 antitrypsin synthesis, decreases globule burden and improves histological measures of liver disease in adults with alpha-1 antitrypsin deficiency: a randomized placebo-controlled phase 2 study
    Webcast links and presentation materials may be accessed on the Events and Presentations page under the Investors section of the Arrowhead website.

Lipocine to Present LPCN 1148 and LPCN 1144 at the EASL Congress 2023

Retrieved on: 
Wednesday, June 7, 2023
Toxicity, EASL, Q&A, Metabolism, SALT, CNS, Central nervous system, Sarcopenia, Congress, Poster, European Association for the Study of the Liver, Cirrhosis, Liver

SALT LAKE CITY, June 7, 2023 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders by leveraging its proprietary technology platform to develop differentiated products, today announced that it will present posters on LPCN 1148 and LPCN 1144 at the forthcoming European Association for the Study of the Liver (EASL) Congress 2023, to take place in Vienna, Austria, June 21 – 24, 2023.

Key Points: 
  • SALT LAKE CITY, June 7, 2023 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders by leveraging its proprietary technology platform to develop differentiated products, today announced that it will present posters on LPCN 1148 and LPCN 1144 at the forthcoming European Association for the Study of the Liver (EASL) Congress 2023 , to take place in Vienna, Austria, June 21 – 24, 2023.
  • A multimodal treatment candidate for sarcopenia in men with decompensated cirrhosis: a randomized, placebo-controlled trial evaluating LPCN 1148
    Dr. Bruno will give a live presentation of this poster followed by a Q&A session during the Poster Tour on June 24th at 15:30-16:15 at the Metabolism, Alcohol, and Toxicity Track hub.
  • The posters will be available on Lipocine's corporate website following the meeting.

CymaBay Therapeutics to Present New Data Highlighting Seladelpar's Unique Activity in Patients with Primary Biliary Cholangitis at The International Liver Congress™ 2023

Retrieved on: 
Wednesday, June 7, 2023
Abstract, EASL, Therapy, Liver disease, PBC, ALP, Alkaline phosphatase, Research and development, Congress, Fibrosis, Primary biliary cholangitis, HIV disease progression rates, A6, Patient, Risk, Itch, UDCA, Conditional sentence, European Association for the Study of the Liver, Safety, Pharmaceutical industry, Liver, Research

NEWARK, Calif., June 7, 2023 /PRNewswire/ -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with significant unmet need, today announced it will make three presentations at the European Association for the Study of the Liver (EASL)'s The International Liver Congress™ 2023. Featured results include novel aspects of the anti-pruritic and anti-fibrotic mechanisms of seladelpar, a first-in-class oral, selective PPARδ agonist, or "delpar," being developed for primary biliary cholangitis (PBC). This year's annual meeting will take place in Vienna, Austria, from June 21-24. 

Key Points: 
  • Featured results include novel aspects of the anti-pruritic and anti-fibrotic mechanisms of seladelpar, a first-in-class oral, selective PPARδ agonist, or "delpar," being developed for primary biliary cholangitis (PBC).
  • Treatment with seladelpar was found to be correlated with decreases in pruritus and Interleukin-31 (IL-31) levels1 in patients with PBC.
  • "It's a privilege to once again be presenting our data at EASL alongside the world's leading researchers in liver disease.
  • The presentations will also be made available after the congress on the CymaBay website, www.cymabay.com

Chemomab Therapeutics Announces Executive Leadership Changes and Provides a Corporate Update

Retrieved on: 
Monday, June 5, 2023
EASL, Pitango, Therapy, NASH, Norwest Venture Partners, Adi, Journal of Accounting and Economics, Clinical trial, CMMB, General partnership, Physiology, MBA, Biomarker, Certified Public Accountant, Doctor of Philosophy, Economics, Health care efficiency measures, Congress, TEL, Data analysis, MD, Patient, Investment, Biophysics, Fattal, Fatty liver disease, CFO, Knowledge, Growth, PSC, Systemic scleroderma, BA, Autoimmunity, Inflammation, Management, Pharmaceutical industry, Finance, Tel Aviv University, Accounting

(Nasdaq: CMMB), a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need, today announced changes to its executive leadership team and provided a corporate update.

Key Points: 
  • (Nasdaq: CMMB), a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need, today announced changes to its executive leadership team and provided a corporate update.
  • "I am excited to resume my corporate leadership responsibilities and look forward to continued engagement with our key stakeholders," said Dr. Mor.
  • "This transition of executive leadership to the company's founding team will focus on maintaining business continuity and ensuring clinical plan execution," continued Dr. Mor.
  • Adi's exceptional corporate leadership skills are complemented by her extensive knowledge in autoimmune, inflammatory and fibrotic diseases and broad experience in developing monoclonal antibodies.

Hepagene Therapeutics to Present at the European Association for the Study of the Liver (EASL) Congress 2023

Retrieved on: 
Thursday, May 25, 2023
EASL, FXR, Dyslipidemia, HPG, NASH, NAS, Serum, GGT, Clinical trial, Pharmacokinetics, CMO, Biomarker, THR, Congress, Plasma, MRI, Animal, Patient, LDL, OCA, Fatty liver disease, Chronic liver disease, RISE, ALT, European Association for the Study of the Liver, Therapy, Safety, IND, Pharmacology, LFC, Pharmaceutical industry, Dietary supplement, Liver

These results provide strong evidence to support continuing efforts in HPG7233 development for NASH and dyslipidemia indications.

Key Points: 
  • These results provide strong evidence to support continuing efforts in HPG7233 development for NASH and dyslipidemia indications.
  • The primary objective of the clinical trial was to evaluate the safety and tolerability of HPG1860.
  • The compound is on track for a Phase 1 study in the second half this year."
  • HPG1860 has shown liver enrichment profile in preclinical studies and displayed robust efficacy with much better safety profile vs OCA in clinical settings.

Chemomab Therapeutics to Participate in Upcoming Scientific Conferences

Retrieved on: 
Wednesday, May 24, 2023
CCL24, EASL, Therapy, NASH, Liver, CMMB, Inflammation, Scleroderma, European Congress of Radiology, Doctor of Philosophy, Fibrosis, TEL, Congress, Patient, European Association for the Study of the Liver, EULAR, PSC, Systemic scleroderma, Primary sclerosing cholangitis, Pharmaceutical industry, Rheumatology

TEL AVIV, Israel, May 24, 2023 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company focused on the discovery and development of innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced upcoming CM-101 data presentations at major European scientific conferences in June 2023, including EULAR23, the European Congress of Rheumatology, and EASL 2023, the Annual Congress of the European Association for the Study of the Liver.

Key Points: 
  • TEL AVIV, Israel, May 24, 2023 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company focused on the discovery and development of innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced upcoming CM-101 data presentations at major European scientific conferences in June 2023, including EULAR23, the European Congress of Rheumatology, and EASL 2023, the Annual Congress of the European Association for the Study of the Liver.
  • Further details of the presented data will be forthcoming.
  • "Our poster presentations at EULAR and EASL highlight the novelty and potential of our unique approach to fibro-inflammatory diseases," said Dale Pfost, PhD, CEO of Chemomab.
  • EULAR23 – European Congress of Rheumatology – Milan, Italy, May 31-June 3, 2023

Intercept Pharmaceuticals Receives FDA Orphan Drug Designation for the Fixed-Dose Combination of OCA and Bezafibrate for the Treatment of Primary Biliary Cholangitis (PBC)

Retrieved on: 
Tuesday, May 16, 2023
Intercept, EASL, Research and development, Bezafibrate, Therapy, PBC, PPAR, Disorder, Congress, Development, Primary biliary cholangitis, Intercept Pharmaceuticals, OCA, European Association for the Study of the Liver, FDA, MPH, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Pharmaceutical industry, MD

MORRISTOWN, N.J., May 16, 2023 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for the fixed-dose combination of obeticholic acid (OCA) and bezafibrate, a peroxisome proliferator-activated receptor (PPAR) agonist, for the potential treatment of individuals with primary biliary cholangitis (PBC).

Key Points: 
  • MORRISTOWN, N.J., May 16, 2023 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for the fixed-dose combination of obeticholic acid (OCA) and bezafibrate, a peroxisome proliferator-activated receptor (PPAR) agonist, for the potential treatment of individuals with primary biliary cholangitis (PBC).
  • “We are pleased that the FDA has granted orphan drug designation for the fixed-dose combination of OCA-bezafibrate, an important component of our long-term strategy and ongoing commitment to people living with PBC,” said M. Michelle Berrey, MD, MPH, President of Research & Development and Chief Medical Officer of Intercept.
  • The planned interim analyses from these Phase 2 studies, in addition to Phase 1 and preclinical data, will serve as the basis of a potential end-of-phase 2 meeting with the FDA.
  • FDA's Office of Orphan Drug Products grants orphan status to support the development of medicines for rare disorders that affect fewer than 200,000 people in the U.S. Orphan drug designation provides certain benefits, including market exclusivity upon regulatory approval, exemption of FDA application fees, and tax credits for qualified clinical trials.

Inventiva reports 2023 First Quarter Financial Information¹ and provides a corporate update

Retrieved on: 
Tuesday, May 16, 2023
EASL, Histology, NASH, Data monitoring committee, Type 2 diabetes, Pharmacokinetics, Liver disease, Kidney, Euronext Paris, Data analysis, Poster, Patient, MD, Financial result, Fatty liver disease, Liver, EIB, Phase, T2D, Pharmaceutical industry, Video game, Medical imaging

R&D expenses for the first quarter were up 38% compared to the first quarter of 2022.

Key Points: 
  • R&D expenses for the first quarter were up 38% compared to the first quarter of 2022.
  • Net cash used in investing activities for the first quarter of 2023 amounted to (€8.4) million, compared to (€0.1) million in the first quarter of 2022.
  • The Company did not recognize revenues for the first quarter of 2023, in line with the first quarter of 2022.
  • The topline results are expected to be published in the middle of the second quarter of 2023.

ENDRA Life Sciences Reports First Quarter 2023 Financial Results and Provides a Business Update

Retrieved on: 
Monday, May 15, 2023
Health, Science, Radiology, Research, Health Technology, Fatty liver disease, EASL, International, De novo, Marketing, Data collection, Temperature, Sale, Congress, MRI, PIN, Non-alcoholic fatty liver disease, NDRA, NAFLD, European Association for the Study of Diabetes, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Medical imaging, Dietary supplement, Security (finance), Liver, Diabetes

ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), today reported financial results for the three months ended March 31, 2023 and provided a business update.

Key Points: 
  • ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), today reported financial results for the three months ended March 31, 2023 and provided a business update.
  • The data will also be used to support commercialization of the TAEUS liver device in Europe and, after FDA clearance, in the U.S.
  • The De Novo pathway is reserved for novel technologies and should assist ENDRA in achieving the strongest market position with TAEUS-optimized claims.
  • In the first quarter, ENDRA participated in the Francophone Society of Diabetes annual meeting.

Vaccitech Reports First Quarter 2023 Financial Results and Recent Corporate Developments

Retrieved on: 
Friday, May 12, 2023
Vaccine, Infection, Antigen, Prostate-specific antigen, EASL, PSA, Cancer, Woman, CHB, Hepatitis B, Research, Autoimmunity, AASLD, AstraZeneca, Șaeș, Public expenditure, Congress, Arbutus, HBsAg, Retirement, CD8, Patient, Data, Laboratory, Non-carious cervical lesions, HPV, Depreciation, Poster, European Association for the Study of the Liver, CD4, Vaccitech, IND, Oxford University Innovation, HBV, Conference, Hepatitis, Safety, OUI, Disease, Pharmaceutical industry, E5, Liver, E4, E7, E2, E6

In April 2023, our Chief Medical Officer, Dr. Meg Marshall, presented interim data from APOLLO at the 35th Annual IPVC.

Key Points: 
  • In April 2023, our Chief Medical Officer, Dr. Meg Marshall, presented interim data from APOLLO at the 35th Annual IPVC.
  • In April 2023, we announced the planned retirement of Chris Ellis, Chief Operating Officer, effective October 31, 2023.
  • Cash position: As of March 31, 2023, cash was $191.3 million, compared to $194.4 million as of December 31, 2022.
  • Revenues: Revenue were $0.5 million in the first quarter of 2023 compared to $15.0 million in the comparable period of the previous year.